4 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 47 points (-0.3%) at 15,521 as of Wednesday, July 24, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 716 issues advancing vs. 2,228 declining with 95 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 1.0%, and Teva Pharmaceutical Industries ( TEVA), down 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Sarepta Therapeutics ( SRPT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sarepta Therapeutics is down $6.79 (-14.6%) to $39.64 on heavy volume. Thus far, 10.4 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $38.39-$46.36 after having opened the day at $45.00 as compared to the previous trading day's close of $46.43.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.5 billion and is part of the health care sector. Shares are up 79.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Sarepta Therapeutics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.18 (-1.4%) to $85.37 on light volume. Thus far, 555,580 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $85.29-$87.48 after having opened the day at $86.95 as compared to the previous trading day's close of $86.55.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $19.5 billion and is part of the health care sector. Shares are up 110.6% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.52 (-1.1%) to $44.67 on light volume. Thus far, 2.2 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $44.66-$45.39 after having opened the day at $45.21 as compared to the previous trading day's close of $45.19.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $73.9 billion and is part of the health care sector. Shares are up 38.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.15 (-0.5%) to $29.27 on light volume. Thus far, 9.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 63.6 million shares. The stock has ranged in price between $29.23-$29.55 after having opened the day at $29.44 as compared to the previous trading day's close of $29.42.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $207.4 billion and is part of the health care sector. Shares are up 17.3% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash